Table 1: Characteristics of included studies for meta-analyses and demographics for included iPD-patients

|  |  |  |
| --- | --- | --- |
|  | | Overall |
| Studies | | 82 |
| Study design = RCT (%) | | 33 (40.2) |
| Medication (%) | |  |
|  | *Adenosine antagonist59-61* | 3 (3.7) |
|  | *Amantadine62, 63* | 2 (2.4) |
|  | *Anticholinergics46, 64-68* | 7 (8.5) |
|  | *Beta-blocker69, 70* | 2 (2.4) |
|  | *Botulinumtoxin71-74* | 4 (4.9) |
|  | *Budipine62, 75, 76* | 4 (4.9) |
|  | *Cannabis77* | 1 (1.2) |
|  | *Dopamine agonists78-102* | 30 (36.6) |
|  | *Gabaergic medication69, 103, 104* | 3 (3.7) |
|  | *Levodopa68, 105-113* | 10 (12.2) |
|  | *MAO-inhibitors112, 114-123* | 12 (14.6) |
|  | *Memantine124* | 1 (1.2) |
|  | *Primidone69* | 1 (1.2) |
|  | *Zonisamide125, 126* | 2 (2.4) |
| Average subjects per study (SD) | | 87.89 (134.59) |
| Participants’ mean age (SD) | | 64.85 (3.31) |
| Mean QualSyst score (SD) | | 0.71 (0.21) |
| Mean UPDRS at baseline (SD) | | 30.18 (8.05) |